Skip to main content English


Bernd Jilma
Univ. Prof. Dr. Bernd JilmaDep. Head

Department of Clinical Pharmacology
Position: Professor

ORCID: 0000-0001-5652-7977
T +43 1 40400 29810

Further Information


Anaphylaxis; Biosimilar Pharmaceuticals; Clinical Trial, Phase I; Drug Interactions; Endotoxemia; Orphan Drug Production; Research Design; Therapeutic Uses

Research group(s)

Research interests

Our focus is to test newly developed drugs in sytemic or lung inflammation and patients with various autoimmune disorders. We combine in vitro, ex vivo and in vivo studies to obtain an integrated insight into pathophysiologic processes and pharmacodynamic actions of drugs. We have a strong background and interest in orphan diseases such as anaphylaxis, thrombotic thrombocytopenic purpura, cold agglutinin disease and antibody mediated rejection of kidney transplants. We are specialised in innovative clinical trial designs including integrated study protocols and basket trial designs including first-in-human trials.

Techniques, methods & infrastructure

The department has got a phase I unit with 10 beds, where we perform first-in-human trials with biologics and small molecules, as well as phase I-III randomized controlled trials. We have established the human endotoxemia model to study drugs in systemic inflammation both for industry and academic purposes. Likewise we have established the endotoxin instillation into lungs in humans to investigate compartimentalized inflammatory responses and drug action. Platelet function tests including the platelet function analyzer and the multiple electrode aggregometry have been utilized in drug-drug interaction studies recently, where pharmacokinetics have been determined by tandem mass spectrometryThrombelastometric measurements and in vivo thrombin generation markers have been used for dose finding of novel anticoagulants and to examine specific pathophysiological changes. Flow-cytometry is used mainly to characterize in vivo changes of cellular blood components under drug treatment or inflammation. Pharmacodynamic models have been developed in mice, rats and guinea pigs to the the pharmacodynamics of recombinant human diamine oxidase, which has been patented by MUV. A histamine challenge model is currently establised in healthy volunteers to compare the effects of various therapeutic interventions to counteract histamine mediated haemodynamic compromise as observed during anaphylaxis.


  • Pharmacodynamics of recombinant human diamine oxidase (rhDAO) (2022)
    Source of Funding: FWF (Austrian Science Fund), Stand Alone Project
    Principal Investigator
  • Cellular Mediators Linking Inflammation and Thrombosis (project part leader) (2013)
    Source of Funding: FWF (Austrian Science Fund), Special Research Programmes (SFB54)
    Principal Investigator

Selected publications

  1. Ay, C. et al. (2022) ‘von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A’, Blood [Preprint]. Available at:
  2. Röth, A. et al. (2021) ‘Sutimlimab in Cold Agglutinin Disease’, New England Journal of Medicine, 384(14), pp. 1323–1334. Available at:
  3. Jäger, U. et al. (2019) ‘Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial’, Blood, 133(9), pp. 893–901. Available at:
  4. Peyvandi, F. et al. (2016) ‘Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura’, New England Journal of Medicine, 374(6), pp. 511–522. Available at:
  5. Hobl, E.-L. et al., 2014. Morphine Decreases Clopidogrel Concentrations and Effects. Journal of the American College of Cardiology, 63(7), pp.630-635. Available at: